179 related articles for article (PubMed ID: 32390563)
1. Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.
Wegeberg AL; Hansen CS; Farmer AD; Karmisholt JS; Drewes AM; Jakobsen PE; Brock B; Brock C
United European Gastroenterol J; 2020 Jul; 8(6):695-704. PubMed ID: 32390563
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal symptoms and cardiac vagal tone in type 1 diabetes correlates with gut transit times and motility index.
Wegeberg AL; Brock C; Ejskjaer N; Karmisholt JS; Jakobsen PE; Drewes AM; Brock B; Farmer AD
Neurogastroenterol Motil; 2021 Jan; 33(1):e13885. PubMed ID: 32573076
[TBL] [Abstract][Full Text] [Related]
3. Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile.
Farmer AD; Pedersen AG; Brock B; Jakobsen PE; Karmisholt J; Mohammed SD; Scott SM; Drewes AM; Brock C
Diabetologia; 2017 Apr; 60(4):709-718. PubMed ID: 28105520
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.
Brock C; Hansen CS; Karmisholt J; Møller HJ; Juhl A; Farmer AD; Drewes AM; Riahi S; Lervang HH; Jakobsen PE; Brock B
Br J Clin Pharmacol; 2019 Nov; 85(11):2512-2523. PubMed ID: 31338868
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation.
Bharucha AE; Low P; Camilleri M; Veil E; Burton D; Kudva Y; Shah P; Gehrking T; Zinsmeister AR
Gut; 2013 May; 62(5):708-15. PubMed ID: 22677718
[TBL] [Abstract][Full Text] [Related]
6. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
7. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
[TBL] [Abstract][Full Text] [Related]
8. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy.
Nakatani Y; Maeda M; Matsumura M; Shimizu R; Banba N; Aso Y; Yasu T; Harasawa H
Diabetes Metab; 2017 Oct; 43(5):430-437. PubMed ID: 28648835
[TBL] [Abstract][Full Text] [Related]
9. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
10. The Glucagon-Like Peptide 1 Receptor Agonist Exenatide Inhibits Small Intestinal Motility, Flow, Transit, and Absorption of Glucose in Healthy Subjects and Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Crouch B; Jones KL; Horowitz M; Rayner CK
Diabetes; 2016 Jan; 65(1):269-75. PubMed ID: 26470783
[TBL] [Abstract][Full Text] [Related]
11. The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.
Shin A; Camilleri M; Busciglio I; Burton D; Smith SA; Vella A; Ryks M; Rhoten D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1453-1459.e4. PubMed ID: 23639598
[TBL] [Abstract][Full Text] [Related]
12. Regional gastrointestinal pH profile is altered in patients with type 1 diabetes and peripheral neuropathy.
Wegeberg AL; Brock C; Brock B; Farmer AD; Hobson AR; Semler JR; Scott SM
Neurogastroenterol Motil; 2018 Nov; 30(11):e13407. PubMed ID: 30062823
[TBL] [Abstract][Full Text] [Related]
13. Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis.
Lee AA; Rao S; Nguyen LA; Moshiree B; Sarosiek I; Schulman MI; Wo JM; Parkman HP; Wilding GE; McCallum RW; Hasler WL; Kuo B
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1770-1779.e2. PubMed ID: 30557741
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
[TBL] [Abstract][Full Text] [Related]
15. Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth.
Roland BC; Ciarleglio MM; Clarke JO; Semler JR; Tomakin E; Mullin GE; Pasricha PJ
J Clin Gastroenterol; 2015 Aug; 49(7):571-6. PubMed ID: 25319735
[TBL] [Abstract][Full Text] [Related]
16. Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial.
Acosta A; Camilleri M; Kolar G; Iturrino J; Szarka LA; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR; Spence SC; Gottesdiener K; Bouras EP; Vazquez-Roque MI
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2312-9.e1. PubMed ID: 26001337
[TBL] [Abstract][Full Text] [Related]
17. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.
Camilleri M; Bharucha AE; Ueno R; Burton D; Thomforde GM; Baxter K; McKinzie S; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G942-7. PubMed ID: 16603730
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
[TBL] [Abstract][Full Text] [Related]
19. Prokinetic effects of mirtazapine on gastrointestinal transit.
Yin J; Song J; Lei Y; Xu X; Chen JD
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G796-801. PubMed ID: 24627566
[TBL] [Abstract][Full Text] [Related]
20. Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
Rotondo A; Janssen P; Mulè F; Tack J
Int J Obes (Lond); 2013 May; 37(5):693-8. PubMed ID: 22846777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
